Calliditas Q3: Improved growth ahead of full approval and an upgraded label - Redeye

Callidita’s strict Tarpeyo (US) product growth is 130% in Q3, and the recorded Q3 sales are 12% below our expectations and 9% below consensus. The number of enrolled patients is 10% below our expectations, and the number of new unique subscribers is 2% below our expectations. The 2023 full sales outlook is re-iterated. The following key milestone is the PDUFA day on 20 December, where we expect Calliditas to secure unconditional approval and an expanded label supported by the solid 2-year eGFR results.

Länk till analysen i sin helhet: https://www.redeye.se/research/955909/calliditas-q3-improved-growth-ahead-of-full-approval-and-an-upgraded-label?utm_source=finwire&utm_medium=RSS